| __timestamp | Axsome Therapeutics, Inc. | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 4279200 | 180753000 |
| Thursday, January 1, 2015 | 6776987 | 224193000 |
| Friday, January 1, 2016 | 21199860 | 197617000 |
| Sunday, January 1, 2017 | 19957616 | 288320000 |
| Monday, January 1, 2018 | 23495055 | 240661000 |
| Tuesday, January 1, 2019 | 53647067 | 276018000 |
| Wednesday, January 1, 2020 | 70244579 | 294216000 |
| Friday, January 1, 2021 | 58060725 | 354881000 |
| Saturday, January 1, 2022 | 57947447 | 361140000 |
| Sunday, January 1, 2023 | 97944000 | 330551000 |
| Monday, January 1, 2024 | 187077000 |
Unlocking the unknown
In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of innovation and future growth. Over the past decade, Grifols, S.A. and Axsome Therapeutics, Inc. have shown contrasting approaches to R&D investment. Grifols, a Spanish multinational, consistently invested heavily, with its R&D expenses peaking at approximately 360 million in 2022, a 100% increase from 2014. Meanwhile, Axsome Therapeutics, a U.S.-based company, demonstrated a more volatile but upward trend, with a staggering 2,200% increase in R&D spending from 2014 to 2023, reaching nearly 98 million. This divergence highlights Grifols' steady commitment to innovation, while Axsome's aggressive ramp-up reflects its strategic push to expand its therapeutic pipeline. As the pharmaceutical landscape evolves, these investment patterns may well dictate the future market leaders.
Research and Development: Comparing Key Metrics for Bristol-Myers Squibb Company and Axsome Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Zoetis Inc. and Grifols, S.A.
Takeda Pharmaceutical Company Limited or Grifols, S.A.: Who Invests More in Innovation?
R&D Spending Showdown: Genmab A/S vs Axsome Therapeutics, Inc.
R&D Insights: How Bio-Techne Corporation and Grifols, S.A. Allocate Funds
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Axsome Therapeutics, Inc.
R&D Spending Showdown: Grifols, S.A. vs Veracyte, Inc.
Grifols, S.A. vs MannKind Corporation: Strategic Focus on R&D Spending
R&D Insights: How Grifols, S.A. and BioCryst Pharmaceuticals, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Axsome Therapeutics, Inc. and TG Therapeutics, Inc.
R&D Spending Showdown: Axsome Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
R&D Spending Showdown: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.